Biotech Values

[iwfal]

The ifn vendors won’t be able to do that because there will continue to patients who undergo 48 weeks of therapy; these will include genotype-1/4 patients who fail to achieve RVR and (probably) all genotype-2/3 patients.

Thought provoking thesis. I am not sure I agree, but I need to do research.

But, a question - why would genotype 2/3s still be treated 48 weeks once their is a direct anti-viral on the market? Unless you are referring to the fact that the G2/3 trials are lagging?